Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 392

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 2
Chunk 392
---
 common stock (inclusive of shares sold pursuant to an overallotment option granted to the underwriters in connection with the offering) through an underwritten public offering at a price of $26.50 per share for aggregate net proceeds of approximately $296.2 million.

There have been no material changes in the planned use of the net proceeds from the follow-on public offering as described in the Registration Statement. We have invested the funds received in short-term and long-term, interest-bearing investment-grade securities and government securities.

Issuer Purchases of Equity Securities

Not applicable. 

ITEM 3.    DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.    MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.    OTHER INFORMATION

95

Table of Contents

Departure of Directors or Certain Officers

Marc Tessier-Lavigne, our co-founder and a Board member, has recently informed us of his intention to step down from the Board effective September 1, 2025 to focus on his increased commitments as CEO and Chairman of Xaira Therapeutics, Inc. The Board extends its gratitude to Marc for his significant contributions to Denali over the past decade. We wish him and Xaira continued success.

Securities Trading Plans of Directors and Executive Officers

No officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the second quarter ended June 30, 2025.

96

ITEM 6.     EXHIBITS

EXHIBIT INDEX

Incorporated by ReferenceExhibitNumberDescriptionFormFile No.NumberFiling Date10.1Executed Affiliate Registration Rights Agreement, dated June 3, 20258-K001-3831110.16/3/202531.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.———Filed herewith31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act.———Filed herewith32.1*Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.———Furnished herewith32.2*Certification of Chief Financial Officer pursuant to Section 906 of the Sarban